M.A. Tanner, MRCP; R. Galanello, MD; C. Dessi, MD; G.C. Smith, MSc; M.A. Westwood, MD; A. Agus, MD; M. Roughton, MSc; R. Assomull, MRCP; S.V. Nair, MRCP; J.M. Walker, MD; D.J. Pennell, MD. A Randomized, Placebo-Controlled, Double-Blind Trial of the Effect of Combined Therapy With Deferoxamine and Deferiprone on Myocardial Iron in Thalassemia Major Using Cardiovascular Magnetic Resonance. „Circulation”. 115 (14), s. 1876–1884, 2007. DOI: 10.1161/CIRCULATIONAHA.106.648790. PMID: 17372174.Full Text.
Brittenham G, Nathan D, Olivieri N, Porter J, Pippard M, Vichinsky E, Weatherall D. Deferiprone and hepatic fibrosis. „Blood”. 101 (12), s. 5089–90; author reply 5090–1, 2003. DOI: 10.1182/blood-2002-10-3173. PMID: 12788794.Full Text.
Wanless I, Sweeney G, Dhillon A, Guido M, Piga A, Galanello R, Gamberini M, Schwartz E, Cohen A. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. „Blood”. 100 (5), s. 1566–9, 2002. DOI: 10.1182/blood-2002-01-0306. PMID: 12176871.Full Text.
Jon Thompson, Patricia Baird & Jocelyn Downie, The Olivieri Report: The Complete Text of the Report of the Independent Inquiry Commissioned by the Canadian Association of University Teachers (Toronto: James Lorimer & Co., 2001).[1]
Olivieri NF, Brittenham GM, McLaren CE, et al.. Long-term safety and effectiveness of iron chelation therapy with oral deferiprone in patients with thalassemia major.. „New Engl J Med.”. 339 (7), s. 417–428, 1998. DOI: 10.1056/NEJM199808133390701. PMID: 9700174.Full Text.
M.A. Tanner, MRCP; R. Galanello, MD; C. Dessi, MD; G.C. Smith, MSc; M.A. Westwood, MD; A. Agus, MD; M. Roughton, MSc; R. Assomull, MRCP; S.V. Nair, MRCP; J.M. Walker, MD; D.J. Pennell, MD. A Randomized, Placebo-Controlled, Double-Blind Trial of the Effect of Combined Therapy With Deferoxamine and Deferiprone on Myocardial Iron in Thalassemia Major Using Cardiovascular Magnetic Resonance. „Circulation”. 115 (14), s. 1876–1884, 2007. DOI: 10.1161/CIRCULATIONAHA.106.648790. PMID: 17372174.Full Text.
Brittenham G, Nathan D, Olivieri N, Porter J, Pippard M, Vichinsky E, Weatherall D. Deferiprone and hepatic fibrosis. „Blood”. 101 (12), s. 5089–90; author reply 5090–1, 2003. DOI: 10.1182/blood-2002-10-3173. PMID: 12788794.Full Text.
Wanless I, Sweeney G, Dhillon A, Guido M, Piga A, Galanello R, Gamberini M, Schwartz E, Cohen A. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. „Blood”. 100 (5), s. 1566–9, 2002. DOI: 10.1182/blood-2002-01-0306. PMID: 12176871.Full Text.
Olivieri N. Patients' health or company profits? The commercialisation of academic research. „Sci Eng Ethics”. 9 (1), s. 29–41, 2003. DOI: 10.1007/s11948-003-0017-x. PMID: 12645227.
nejm.org
nejm.org
Nancy F. Olivieri, Gary M. Brittenham, Doreen Matsui, M.D., Matitiahu Berkovitch, M.D., Laurence M. Blendis, Ross G. Cameron, Robert A. McClelland, Peter P. Liu, Douglas M. Templeton & Gideon Koren. Iron-Chelation Therapy with Oral Deferiprone in Patients with Thalassemia Major. „New England Journal of Medicine”. 332, s. 918-922, 1995. (ang.).
content.nejm.org
Olivieri NF, Brittenham GM, McLaren CE, et al.. Long-term safety and effectiveness of iron chelation therapy with oral deferiprone in patients with thalassemia major.. „New Engl J Med.”. 339 (7), s. 417–428, 1998. DOI: 10.1056/NEJM199808133390701. PMID: 9700174.Full Text.
Olivieri NF, Brittenham GM, McLaren CE, et al.. Long-term safety and effectiveness of iron chelation therapy with oral deferiprone in patients with thalassemia major.. „New Engl J Med.”. 339 (7), s. 417–428, 1998. DOI: 10.1056/NEJM199808133390701. PMID: 9700174.Full Text.
M.A. Tanner, MRCP; R. Galanello, MD; C. Dessi, MD; G.C. Smith, MSc; M.A. Westwood, MD; A. Agus, MD; M. Roughton, MSc; R. Assomull, MRCP; S.V. Nair, MRCP; J.M. Walker, MD; D.J. Pennell, MD. A Randomized, Placebo-Controlled, Double-Blind Trial of the Effect of Combined Therapy With Deferoxamine and Deferiprone on Myocardial Iron in Thalassemia Major Using Cardiovascular Magnetic Resonance. „Circulation”. 115 (14), s. 1876–1884, 2007. DOI: 10.1161/CIRCULATIONAHA.106.648790. PMID: 17372174.Full Text.
Brittenham G, Nathan D, Olivieri N, Porter J, Pippard M, Vichinsky E, Weatherall D. Deferiprone and hepatic fibrosis. „Blood”. 101 (12), s. 5089–90; author reply 5090–1, 2003. DOI: 10.1182/blood-2002-10-3173. PMID: 12788794.Full Text.
Wanless I, Sweeney G, Dhillon A, Guido M, Piga A, Galanello R, Gamberini M, Schwartz E, Cohen A. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. „Blood”. 100 (5), s. 1566–9, 2002. DOI: 10.1182/blood-2002-01-0306. PMID: 12176871.Full Text.
Olivieri N. Patients' health or company profits? The commercialisation of academic research. „Sci Eng Ethics”. 9 (1), s. 29–41, 2003. DOI: 10.1007/s11948-003-0017-x. PMID: 12645227.
